Transitioning into 'pharma' is a challenging career decision since it is very different from working in individual patient care. However, for many, the opportunity to develop innovative medicines, communicate their benefits, and, thus, influence the care of thousands of patients at a time is a rewarding alternative. The current paper explores the "Why-What-How" of successful physician careers within the pharmaceutical industry, realizing both professional and philosophical perspectives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40290-020-00338-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comorbidities, drug-resistance and length of hospital stay among tuberculosis inpatients in Northeastern China: a retrospective observational study from 2013 to 2021.
BMC Infect Dis
December 2024
Infectious Disease Hospital of Heilongjiang Province, No. 1 Jian She Street, Hulan District, Harbin, Heilongjiang, 150500, China.
Background: Tuberculosis (TB) remains a significant global health issue. Drug-resistant TB and comorbidities exacerbate its burden, influencing treatment outcomes and healthcare utilization. Despite the growing prevalence of TB comorbidities, research often focuses on single comorbidities rather than comorbidity patterns.
View Article and Find Full Text PDFChitinases are important virulence factors in Vibrio for degrading the chitin-rich barrier of shrimp.
Int J Biol Macromol
December 2024
School of Biology and Biological Engineering, South China University of Technology, Guangzhou Higher Education Mega Center, Guangzhou, Guangdong 510006, PR China. Electronic address:
Vibrio-induced diseases pose a significant threat to shrimp aquaculture. While the mechanisms underlying Vibrio penetration of shrimp shells and the gastrointestinal tract remain unclear, this study implicates chitinases as critical virulence factors. Despite their inability to utilize chitin or shrimp shells as sole carbon and nitrogen sources, three major shrimp pathogens-V.
View Article and Find Full Text PDFAdolescents' perceptions, experiences, and reactions to "fake" vaping devices.
Drug Alcohol Depend
December 2024
Center for Tobacco Control Research and Education, University of California San Francisco, 95 Kirkham Street Box 1361, San Francisco, CA 94143, United States.
Unlabelled: Use of electronic cigarette (vaping) devices, whether to inhale nicotine, cannabis, or other substances, may pose health risks to adolescents. Those risks could be heightened when a vaping device is "fake," a term we use to include inauthentic, knockoff, counterfeit, and/or adulterated devices, an issue exemplified by the Electronic Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) outbreak of 2019-2020.
Methods: Investigators completed in-depth, semi-structured interviews in 2020-2021 with 47 California adolescents (ages 13-17) who used nicotine products.
The UP1 domain is essential for the facilitation effect of HnRNP A1 on PRRSV-2 replication.
Virology
December 2024
Key Laboratory of Veterinary Biological Products, College of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou, 450046, China. Electronic address:
Porcine reproductive and respiratory syndrome virus (PRRSV) infection causes reproductive failure and respiratory distress and is a serious threat to the swine industry, given its continuous and rapid emergence. The knowledge of viral-host interaction could facilitate anti-PRRSV drug development. HnRNP A1 is an abundantly expressed protein which associates with RNA metabolic processes and plays multifarious roles during the reproduction cycle of multiple viruses.
View Article and Find Full Text PDFPurpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!